Why the latest Azenta event matters for investors

Azenta (AZTA) has just completed the previously announced sale of its B Medical Systems business to Thelema S.à r.l. This represents a portfolio shift that places more emphasis on its core life sciences operations.

For investors, this completed transaction creates a fresh reference point to reassess how Azenta’s sample management and multiomics segments, which together generated US$596.5 million in revenue, compare with the company’s current market value of about US$1.17 billion.

Azenta’s latest moves come after a mixed share price run, with the stock up around 8% on a 3 month share price return but down about 27% on a 1 year total shareholder return. This suggests longer term momentum has been weak even as short term sentiment has improved slightly following portfolio changes and its recent additions to the Russell 2000 Defensive and Russell 2000 Value Defensive Indexes.

If you are weighing Azenta against other opportunities in the sector, it can be useful to see how investors are positioning around healthcare focused AI plays using the 40 healthcare AI stocks.

The reshaped Azenta now leans more heavily on its life sciences engine, but a focused business is not the same as a well priced stock. So how does today’s US$1.17b valuation stack up against the core operations?

Most Popular Narrative: 6.5% Undervalued

According to the most followed narrative on Azenta, a fair value of $26.20 sits modestly above the last close at $24.51. This frames the stock as slightly below that narrative view, while still close enough that assumptions really matter.

The company's streamlined cost structure, as a result of structural realignment and deployment of the Azenta Business System (ABS), has already yielded substantial G&A reductions and improved working capital, which together enable sustainable free cash flow generation and margin stability even amid near-term macro headwinds.

Curious what is baked into that $26.20 figure? The narrative leans on steady top line expansion, meaningful margin repair, and a richer earnings multiple than many peers. The full set of assumptions is where the story gets interesting.

Result: Fair Value of $26.20 (UNDERVALUED)

However, the Azenta narrative could be challenged if delays in higher margin equipment orders persist, or if softness in Gene Synthesis and Sanger Sequencing revenues deepens.

Next Steps

If this Azenta story feels finely balanced, move quickly to review the same data points yourself. Then weigh them against the 3 key rewards.

Looking for more investment ideas beyond Azenta?

If Azenta has your attention, do not stop here. Broadening your watchlist with other clear ideas can help you spot opportunities others might overlook.

• Expand your hunt for potential upside by scanning 44 high quality undervalued stocks that pair quality fundamentals with prices that may sit below their underlying metrics.
• Strengthen your focus on resilience by reviewing 72 resilient stocks with low risk scores that score well on stability while still offering room for investor interest.
• Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems that combine solid financial traits with limited existing market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.